Poor
Major Non-Aligned
Patient Risk:
Medium
Summary
Only one interaction claim (aspirin increasing bleeding risk) is supported by the provided label excerpts; multiple other interaction and counseling claims are unsupported or only partially supported, and one indication-related claim is broader than the label language provided.
Category Scores
Accurate Statements
Aspirin can increase the risk of bleeding when taken with Vascepa.
5 WARNINGS AND PRECAUTIONS (5.3 Bleeding): bleeding incidence greater in patients receiving concomitant antithrombotic medications, such as aspirin (and others).
Unsupported Statements
Antacids and acid reducers can decrease the absorption of Vascepa.
No support in the provided label excerpts (Indications, 5.3 Bleeding, and the provided 7.1 excerpt do not mention antacids/acid reducers or absorption changes).
Decreased absorption of Vascepa can reduce its effectiveness.
No support in the provided label excerpts.
Anti-inflammatory medications (ibuprofen, naproxen) can increase the risk of bleeding when taken with Vascepa.
No support in the provided label excerpts for NSAIDs specifically or for this interaction.
Decongestants (pseudoephedrine, phenylephrine) can increase blood pressure, which can be problematic when taken with Vascepa.
No support in the provided label excerpts.
Diuretics (furosemide, hydrochlorothiazide) can increase the risk of dehydration when taken with Vascepa.
No support in the provided label excerpts.
Aspirin can increase the risk of bleeding when taken with Vascepa, especially in patients with a history of bleeding disorders.
Provided excerpt supports increased bleeding risk with concomitant antithrombotic medications such as aspirin, but the 'especially in patients with a history of bleeding disorders' qualifier is not shown in the supplied label text.
Antihistamines can increase the risk of dizziness and lightheadedness when taken with Vascepa.
No support in the provided label excerpts.
Diphenhydramine is an example antihistamine that can increase the risk of dizziness and lightheadedness when taken with Vascepa.
No support in the provided label excerpts.
Vascepa should not be taken with other omega-3 fatty acid supplements because this may increase the risk of bleeding.
Provided label excerpt discusses monitoring with concomitant anticoagulants/antiplatelet agents and notes prolongation of bleeding time in published omega-3 fatty acid studies, but does not include a statement restricting other omega-3 supplements or a prohibition tied to them.
Patients should inform their healthcare professional about all medications they are taking.
No support in the provided label excerpts.
Contradictions
Important Omissions
The indication claim is broader than the provided label language: the label specifies use (1) as adjunct to diet to reduce TG in adults with severe hypertriglyceridemia (≥500 mg/dL) and (2) as adjunct to maximally tolerated statin therapy to reduce risk of specific cardiovascular events in adults with elevated TG (≥150 mg/dL) with specified CV disease/diabetes risk factors. The extracted claim states only that it 'is used to lower triglyceride levels' without these limitations.
Importance:
Moderate
Bleeding risk warning in the provided excerpt is tied to concomitant antithrombotic medications (e.g., aspirin, clopidogrel, warfarin). The extracted claims introduce several other drug-class-specific effects (antacids/acid reducers, NSAIDs, decongestants, diuretics, antihistamines) without label support, and the label’s monitoring language for patients on concomitant anticoagulants/antiplatelet agents is not reflected in the extracted set as an aligned recommendation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported interaction/counseling claims could mislead regarding what to avoid or monitor; only aspirin/bleeding risk is supported by the supplied label excerpts. While the supported aspirin/bleeding risk is consistent with the label, the broader unsupported interaction set increases the chance of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Major Non-Aligned
Primary Issue
Most interaction and counseling claims are absent from the provided label excerpts; only one (aspirin/bleeding) is supported. One indication-related claim is also broader than the label limitations shown.
Suggested Improvement
Restrict claims to what is supported by the provided label text (e.g., bleeding risk with concomitant antithrombotic agents such as aspirin/warfarin and monitoring language), and avoid class-specific interaction claims (antacids/acid reducers, ibuprofen/naproxen, decongestants, diuretics, antihistamines, additional omega-3 supplements) unless corresponding label excerpts are provided.